Worldwide Single Cell Analysis (SCA) Market Forecasted to Grow at 13% p.a. over the Next Three Years, Reaching $1.7B by 2025 – Market Report by DeciBio Consulting LLC

LOS ANGELES–(BUSINESS WIRE)–#decibio–According to a comprehensive market report authored by DeciBio Consulting LLC, Single-Cell Analysis (SCA): Market Size, Segmentation, Growth, Competition, and Trends (2019-2025), the global single-cell analysis market is predicted to reach $1.7B by 2025. This growth will be driven by expansion in new applications and offerings, such as FFPE-compatibility and instruments for low- and high-throughput customers.

This fifth edition of DeciBio’s single-cell analysis (SCA) report takes an updated and comprehensive look at the SCA landscape. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key SCA market segments.

Previous editions of this report have focused exclusively on single-cell genomics applications. However, as proteomic and multiomic single-cell applications have been increasingly commercialized and used, this edition of the report has expanded to cover proteomic and multiomic applications as well.

SCA approaches have rapidly gained traction, as they offer the ability to assess the biology of individual cells – compared to bulk analysis approaches that only provide one readout for an entire cell population. These approaches are uniquely positioned to revolutionize biology by shedding light on cellular heterogeneity, which has important implications across biology and diseases. Studies thus far have already provided important insights, and recent technical advances continue to help increase the study size and growth in this field.

Report Details
Research Methods	Secondary research: analysis of quarterly and annual reports, earnings call transcripts, congress abstracts, company websites Primary research: interviews with 25 single cell analysis stakeholders across the U.S. and E.U. in academia and biopharma Proprietary Databases / Analysis: use of internal databases and tools (e.g., BioTrack, Dexter expert network)
2025 Market Size	$1.7 billion
CAGR (2019-2025)	19%
Base Year	2019
Forecast Period	2019-2025
Market / Forecast Currency	USD
Report Coverage	Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis
Segments Covered	Customer (academia, biopharma, applied markets, clinical) Workflow (tissue dissociation, sample preparation, downstream analysis) Analyte (RNA, DNA, epigenetic, protein, multiomic, other) Field-of-Study (oncology, immunology, microbiology, basic cell biology, stem cell biology, neurology, other, non-specific) Product Type (instruments, reagents, services, other) Geography (U.S., Europe, China, Asia Pacific, Rest-of-the-World)

Learn more about DeciBio’s Single Cell-Analysis Market Report Fifth Edition: Q1 2023

www.decibio.com/market-reports/single-cell-genomics-market-assessment-report

Single-Cell Analysis Companies Profiled:

• 10x Genomics
• BD
• Berkeley Lights
• Bio-Rad
• Cellenion
• Cell Microsystems
• CellSorter
• DeepCell
• Dolomite Bio
• Fluent Biosciences
• Fluxion Biosciences
• Honeycomb Biotechnologies
• Illumina
• IsoPlexis
• Menarini Silicon Biosystems
• MGI
• Miltenyi Biotec
• Mission Bio
• Namocell
• NanoCellect
• Nanostring
• Parse Biosciences
• Qiagen
• Singleron
• Standard BioTools
• S2 Genomics
• StemCell Technologies
• Takara Bio

Single-Cell Analysis Market Analysis:

Market Drivers

• New applications, namely multiomics approaches, are increasing utility – e.g.,10x Genomics driving additional applications (e.g., FFPE-compatibility) on a large and growing install base
• Growth in biopharma utilization, where single-cell methods are used to support drug discovery; the advent of FFPE-compatible single-cell analysis allows biopharma to tap into archived samples
• Newer offerings targeting both low-throughput and high-throughput customers are expanding the user base – e.g., 10x Genomics’ Chromium X/iX, Parse Biosciences’ Evercode
• Falling sequencing costs are lowering the barrier for new users of SCA and allowing existing users to increase their throughput / scale of experiments

Market Moderators

• High assay costs and associated sequencing costs limit adoption / throughput of users
• Spatial-omics, another expensive research tool, might compete for spend with single-cell methods
• Emerging instrument-free approaches (e.g., Parse, Fluent, Scale) might push the market towards less capital-intensive approaches / commoditization
• Challenges in data analysis and data integration as throughput and data complexity grows
• Limited short-term clinical applications (though cell therapy regulations could shift this)

About DeciBio

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

Contacts

Rebecca Burnham

Rebecca.burnham@decibio.com
310.451.4510